Hi-Tech Pharmacal has bought the rights to make and market a generic version of a drug used to treat candidiasis, a yeast infection of the mouth.
The drug, Nystatin oral suspension, is now in the FDA’s generic approval process, the agency's abbreviated new drug application.
Amityville-based Hi-Tech said it is paying up-front and in royalties for generic rights from Bausch + Lomb, an eye health care company, but did not say how much it's paying.
“Hi-Tech intends to launch Nystatin oral solution in all commercially available fill sizes as soon as it satisfies all applicable FDA requirements,” the company said. The annual market for Nystatin oral solution is $23 million, Hi-Tech said.